Cabaletta Bio, Inc. Common Stock
N/A
USD
N/A
N/A
...
Chart
Financials
Description
CABA Company Description
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) has the potential to be applied across a broad range of autoimmune diseases.
CABA Stock Smart Score
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?
Sign Up to view CABA Smart Score
Score Breakdown
CABA Company Description
Show More
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) has the potential to be applied across a broad range of autoimmune diseases. Show Less
All
Government
Consumer Interest
SEC Filings
ESG/Other
Recent trades of CABA by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by CABA's directors and management
Government lobbying spending instances
U.S. Patents
New patents grants
Government Contracts
Federal grants, loans, and purchases
Twitter
Followers on CABA's company Twitter account
WallStreetBets
Number of mentions of CABA in WallStreetBets Daily Discussion
CABA News
Recent insights relating to CABA
CNBC Recommendations
Recent picks made for CABA stock on CNBC
Top ETF Holders
ETFs with the largest estimated holdings in CABA
Corporate Flights
Flights by private jets registered to CABA
Our Analysis